A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

NCT02018536 ↗

Phase 1 Completed 48 enrolled Janssen R&D Ireland

RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of the study is to investigate the safety, tolerability, and pharmacokinetic (what the body does to a medication) of GSK2336805 alone and with the co-administration of TMC435 in healthy Japanese participants.

Timeline

Start: 2013-10
Primary completion: 2014-03
Completion: 2014-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GSK2336805	Unknown	30 mg	Oral
Subject	GSK2336805	Unknown	60 mg	Oral
Subject	GSK2336805	Unknown	120 mg	Oral
Subject	Simeprevir	Small molecule	100 mg	Oral
Subject	Simeprevir	Small molecule	150 mg	Oral

Indications

No indication recorded.